Skip to content

Public FDA record

Z-1772-2022: The Randox Serology I Positive Control contains the following analytes in human based plasma: Anti HIV 1/

Recall record Z-1772-2022 for Randox Laboratories Ltd.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1772-2022
Company in FDA record
Randox Laboratories Ltd.
FDA classification date
Sep 19, 2022
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

***Update** :HBsAg analyte is also Non-Reactive on the Ortho Vitros analyser as well as the Beckman Coulter DxI. Randox Serology I Positive Control will test negative (Non-Reactive) for Marker HBsAg resulting in delay in reporting patient results due to the positive control O36SR testing negative (Non-Reactive) for Marker HBsAg

Source facts

Action
****UPDATE*** Randox issued Updated Urgent Medical Device Correction REC611 Rev 2 dated 10/7/22. Letter states: The Randox Serology I Positive Control SR10352 lot 036SR will test negative (Non-Reactive) for Marker HBsAg using the Beckman Coulter Dxl and Ortho Vitros methods. Randox can confirm the Positive control will produce a Reactive result on the Abbott Alinity, Siemens Atellica, Biomerieux Vidas and Roche e411 methods. Randox cannot guarantee that the control will produce a Reactive result on methods not included on this notice. The distributors and customers will be instructed to: " Discuss the contents of this notice with your Medical Director. " Complete and return the response form 12187-QA to technical.services@randox.com within five working days. Randox issued Urgent Medical Correction Notification (REC611) dated August 2, 2022 to the distribution center within the USA. The distributor will then contact the customer directly. The initial contact and the follow up contact will be via email. Letter states reason for recall, health risk and action to take: Randox Serology I Positive Control SR10352 lot 036SR will test negative (Non-Reactive) for Marker HBsAg using the Beckman Coulter Dxl method. The Positive control will produce a Reactive result on the Abbott Alinity, Siemens Atellica and Biomerieux Vidas methods. " Discuss the contents of this notice with your Medical Director. " Complete and return the response form 12187-QA to tech nical.services@randox.com within five working days. Transmission of Field Safety Notice: Send a copy of the FSN to all affected customers and to those who need to be aware within your organization.
Initiated
2022-08-01
Root cause
Process change control
Terminated
2024-12-13
Distribution
US Nationwide distribution in the states of WV, NC.
Recall number
Z-1772-2022
Recall status
Terminated
CDRH record ID
195709
FDA classified
2022-09-19
Recall event number
90777

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗